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Acute pancreatitis  from cellular signalling to complicated clinical
course
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Abstract
Acute pancreatitis (AP) is a common disease that has a mild to moderate course in most cases. During the last decade, a
change in diagnostic facilities as well as improved intensive care have influenced both morbidity and mortality in AP. Still,
however, a number of controversies and unresolved questions remain regarding AP. These include prognostic factors and
how these may be used to improve outcome, diagnostic possibilities, their indications and optimal timing, and the systemic
inflammatory reaction (systemic inflammatory response syndrome  SIRS) and its effect on the concomitant course of the
disease and potential development of organ failure. The role of the gut has been suggested to be important in severe AP, but
has recently been somewhat questioned. Despite extensive research, pharmacological and medical intervention of proven
clinical value is scarce. Various aspects on surgical interventions, including endoscopic sphincterotomy, cholecystectomy
and necrosectomy, as regards indications and timing, will be reviewed. Last, but not least, are the management of late
complications and long-term outcome for patients with especially severe AP.
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Definition
To date, the most generally used definition of acute
pancreatitis (AP) and its severity has been the Atlanta
classification [1]. According to this, AP is an acute
inflammatory process in the pancreas with various
degrees of involvement of local or other organ
systems. Severe AP, occurring in 1520% of all cases
of AP, is defined as the occurrence of organ failure,
]3 Ranson criteria, an APACHE II score ]8 or local
complications like pancreatic necrosis, pseudocyst
development or pancreatic abscess formation. The
Atlanta classification has been discussed concerning
its relevance in defining the true severity of AP and it
has been reported that resolution of organ failure
within 48 h suggests a good prognosis [2]. A number
of prognostic factors, as will be mentioned and
discussed below, probably have to be included in an
updated version on severity scoring in AP.
Incidence
The reported incidence of AP has varied widely, but
seems to be about 300 cases or more per million
inhabitants and year in western Europe [35]. The
aetiology varies, but dominating factors are biliary
disease (now in most series representing about 40% of
all cases of AP), alcohol disease and a variety of causes
like post-ERCP, hyperparathyroidism (HPT), immu-
nological causes and side effects of pharmacological
treatment. Recurrent disease is seen in at least 20% of
patients with AP and a severe (usually necrotizing)
pancreatitis has been reported in general in 1520%,
with an associated mortality rate ranging up to
20% [5].
Determination of severity
The most commonly used severity determination has
been the Atlanta classification, discriminating be-
tween mild and severe AP, but in addition to
pancreatic necrosis, this has also taken acute fluid
collection, pancreatic abscesses and pseudocyst for-
mation into consideration [1]. Of less use today are
the Ranson criteria [6] and the Glasgow score [7].
Still valid for patients with critical illness and roughly
discriminating between severe and mild disease is the
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APACHE II score, in cases of AP often used in an
attempt to discriminate patients with prognost-
icated severe AP with an APACHE II score in general
above 8 [8,9]. From a radiological point of view, the
computed tomography (CT)-based Balthazar score
with a grading from A to E has been, and is still to
some extent used [10]. In patients treated in the
intensive care unit (ICU) due to organ failure, more
recent organ failure scores like the SOFA (Sepsis-
related Organ Failure Assessment) score can be
applied [11].
Prognostic factors
The first episode of AP has been regarded as the
potentially severe one, with a risk of resulting in a
complicated course and subsequent mortality. How-
ever, attacks of severe AP may occur also in recurrent
episodes of AP and may thus also be associated with
mortality. It has been demonstrated that mortality
also occurs in patients with recurrent AP, although the
associated mortality rate is reported to be about half
of that seen in patients with their first attack of AP [5].
Age has often been demonstrated as a prognostic
factor. An age exceeding 65 years been associated
with an increased mortality [12]. This is most
probably due to associated underlying diseases result-
ing in an increased ASA (American Society of
Anesthesiology) score and an impaired capability of
coping with critical illness and its complications in
general.
Obesity, defined as a body mass index (BMI)
exceeding 30, has been identified as a prognostic
factor of importance, increasing both morbidity and
mortality. The reasons for this are still not fully
elucidated, but may include an increased number of
underlying diseases and increased severity of disease
caused by extrapancreatic factors like pulmonary
dysfunction, exacerbated by the increased abdominal
pressure in the obese patient [13].
Prognostic factors of clinical importance at admis-
sion to hospital are still rarely defined, but are of
course of outmost importance to improve future
management of AP patients. Hypovolaemia resulting
in a systolic blood pressure B100 mmHg at admis-
sion has been shown to correlate with an increased
mortality in patients with expected severe AP [14].
This probably illustrates the systemic dissemination of
disease and an increase in endothelial barrier perme-
ability early on, as a consequence of more profound
SIRS in severe disease, correlating with the magnitude
of the pro-inflammatory response.
The levels of activation peptides, i.e. the cleavage
products of pancreatic pro-enzymes, may be of
potential future clinical use [15]. A rise in the level
of trypsinogen activating peptide (TAP) in urine
during the first days has been reported to correlate
with levels of C-reactive protein (CRP), levels of
interleukin-6 (IL-6), the extent of pancreatic necrosis
and severity [16].
The magnitude of the pro-inflammatory response
seems to correlate with severity and the concomitant
course of the disease. CRP levels exceeding 150 mg/L
within the first 72 h of the disease correlate with the
occurrence of necrotizing pancreatitis and the degree
of severity [1719]. Levels of the pro-inflammatory
cytokines IL-6 and IL-8 may be of future clinical use,
as levels have been found to correlate with severity
and thus may represent prognostic factors, in time
preceding the increase in CRP [20,21]. Also of
prognostic importance is the persistent SIRS asso-
ciated with multiple organ dysfunction syndrome
(MODS) and mortality, as has been demonstrated
recently [22]. Furthermore, pancreatic necrosis, its
extent and especially potential bacterial contamina-
tion, highly correlate with the prognosis in AP
[23,24].
The occurrence of organ dysfunction and not least
the number of failing organs correlate with mortality,
as has been demonstrated both in severe AP, but also
in other types of critical illness [5,25]. It should be
stated that more recent findings emphasize that the
progression of organ failure is associated with mor-
tality, but early organ dysfunction frequently resolves
spontaneously and thereby is without demonstrable
impact on prognosis and has no association with
mortality [26].
Inflammatory response and course in acute
pancreatitis
The acute phase response during the course of AP is
the net response of the pro-inflammatory and simul-
taneously occurring anti-inflammatory response. Dur-
ing the initial phase this may frequently result in a
hyperinflammatory state, the development of SIRS
and potentially organ dysfunction. Less known is
the hypoinflammatory state (compensatory anti-in-
flammatory response syndrome  CARS) that may
follow later on during the course of critical illness, as
initially described by Bone et al. [27,28]. Hypotheti-
cally, during this later phase, the patient may be more
vulnerable to, for example, bacterial translocation or
the trauma added by a surgical intervention. This
could potentially lead to the combination of MODS
and sepsis (Figures 1 and 2), as seen during later
phases of critical illness [27,28].
Mortality in severe AP may range up to 20% or
more. As mentioned, mortality is most often caused
by organ dysfunction during the initial phase and
frequently by the combination of MODS and sepsis
during the later phase of disease (after the initial
week). Less reported is the frequent prehospital
mortality encountered, especially in patients with
underlying alcohol-induced pancreatitis, who may
account for up to one-third of the total number of
patients succumbing to AP. It has also been reported
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that 3040% of patients with AP are not diagnosed
before autopsy. Despite improvements in the initial
resuscitation of patients with AP, mortality during the
first week (caused by organ dysfunction) is still
reported to be in the range of 3550% of total deaths
in pancreatitis after admission [5,2931].
Gut barrier failure and systemic inflammatory
response
Gut barrier failure in severe AP, as an example of
critical illness, does not just involve the gut barrier and
an increase in permeability (as seen both experimen-
tally and clinically) [3235], leading to translocation
of enteric bacteria, for example. The gut barrier
failure also involves alterations in immunocompetent
cells within both the gut wall and adjacent lymph
nodes (gut associated lymphoid tissue  GALT).
Overall, a number of underlying changes have to
occur to allow failure of the intestinal barrier to
develop [36]. These mechanisms involve a decrease
in both the systemic and intestinal microcirculation,
leading to ischaemia and reperfusion injury and
the release of oxygen free radicals. The increases in
permeability, as mentioned above, are essential in the
development of barrier failure and include an increase
of both the endothelial and the mucosal epithelial
barrier permeability. The change in systemic and local
immune function may give rise to an exaggerated
initial hyperinflammatory response, with the excessive
release of various cytokines and mediators. In cases
with severe AP, intestinal motility is impaired, thereby
decreasing enteric bacterial clearance by the normal
propulsive activity, allowing overgrowth of enteric
bacteria. By action of bacterial lipases and proteases,
for example, morphological changes may occur,
followed by attachment and colonization of bacteria
to the mucosa. Some of these mechanisms are
summarized in Figure 3.
The magnitude of the acute inflammatory response
and release of cytokines and mediators correlates with
the development of systemic complications and organ
dysfunction [3740]. Persistent SIRS is associated
with the development of MODS and mortality and
represents an early prognostic indicator of the degree
of severity in AP [22]. It has gradually become more
evident that ischaemia and reperfusion injury, to-
gether with increases in endothelial barrier perme-
ability, may represent the most important and central
mechanisms. In the clinical setting, initial aggressive
fluid resuscitation can minimize the effect of ischae-
mia and reperfusion injury and this concept is now
introduced in modern management of critical illness,
including severe AP [14,32,41,42].
Pharmacological and medical intervention
Despite extensive research efforts, there is a lack of
specific medical/pharmacological interventions in AP
that have been of any proven clinical value. Among
studied agents, the use of protease inhibitors has been
unsuccessful, and no effect has been proven by the use
of somatostatin analogues. In a meta-analysis, studies
using the platelet activating factor antagonist Lexipa-
fant failed to demonstrate any significant difference in
multiple organ failure or mortality [43]. However,
lessons can be learned from general management in
critical illness, that probably can also be applied
in patients with severe AP. Low dose steroids have
been reported to decrease mortality in septic shock
and adrenal failure [44]. Of profound interest and of
rapid clinical implementation is the study demonstrat-
ing benefits of intensive insulin treatment, keeping
blood glucose levels within the lower range. This
reduces mortality in intensive care, especially in cases
with multiple organ dysfunction and an identified
septic source [45].
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One of the interesting future lines of development
may be the use of the anti-inflammatory properties
provided by anticoagulatory agents. A complex cross-
talk seems to be going on between inflammation and
coagulation. Already in clinical use is recombinant
activated protein C that has been reported to decrease
mortality in patients with severe sepsis [46], decreas-
ing the inflammatory response [47]. It also seems that
anti-inflammatory effects can be seen following the
administration of other inhibitors of different steps in
the coagulation cascade. Anti-inflammatory effects
have thus been reported experimentally following
the administration of tissue factor pathway inhibitor
and by inhibiting factor VIIa and, to some extent,
factor Xa [48,49].
Antibiotic prophylaxis
Several studies using different types of antibiotics in
patients with different severity, sometimes mixing
both mild and severe AP, have pointed out an overall
beneficial effect. In a meta-analysis, a positive effect
on outcome has been reported in severe (necrotizing)
acute pancreatitis [50,51]. However, some reports
have pointed out the risk of fungal infections. In
particular, candida infection has been reported to be
associated with an increase in mortality [52]. More
recently, meta-analyses have reported that only anti-
biotic prophylaxis using carbapenem has been of value
[43] and the use of prophylactic antibiotics does not
prevent infection of the pancreatic necrosis or the
associated mortality in acute necrotizing pancreatitis
[53]. Thus, at present, the use of antibiotic prophy-
laxis is controversial. Improved general management,
including initial fluid resuscitation, early enteral
nutrition and the administration of, for example,
probiotics, may provide a better ‘upstream’ effect,
preventing permeability changes and translocation
from the gut.
Enteral nutrition  of value in AP?
The use of early enteral nutrition in AP has been
studied in a number of publications and summarized
findings point to its feasibility, cost reduction, a
decrease in septic complications, hospital stay, mod-
ulation of the inflammatory response and facilitation
of gut function. Weaknesses, though, have been that
most studies have included only a limited number of
patients, with in general a substantial delay before the
initiation of enteral nutrition, using a non-defined
enteral formula and a mix of patients with varying
severity of disease [5459]. By using the addition of
probiotics (Lb. Plantarum 299) to enteral nutrition in
patients with prognosticated severe AP, the incidence
of sepsis and need for surgical intervention could be
significantly decreased, as evaluated in 45 patients
[60]. By tradition, a more distal positioning of the
enteral tube has been advocated, aiming at reaching a
position of the tip at about the level of the ligament of
Treitz. Enteral nutrition provided through a nasogas-
tric tube has also been successful in severe AP in 22 of
26 patients [61]. The use of nasogastric early enteral
nutrition has also been demonstrated to be feasible
and without side effects as compared with traditional
treatment of ‘pancreatic rest’, and this regime pro-
vided better blood glucose control in patients with
prognosticated severe AP [62]. In patients with mild
AP, a recent randomized clinical study has demon-
strated that by allowing patients to eat directly,
hospital stay decreased by one-third without any
notable side effects or increase in, for example,
refeeding pancreatitis [63].
Endoscopic retrograde cholangiography (ERC)
and sphincterotomy
The role of ERC and sphincterotomy in biliary
pancreatitis has been widely debated, although
randomized clinical studies on the subject are
limited. At least previously, a more aggressive, i.e.
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Figure 3. Tentative interacting mechanisms in acute pancreatitis.
Acute pancreatitis 417
early, ERC intervention has been advocated. In
patients with lack of treatment effect within 48 h,
bile duct clearance was reported to result in a
decrease in morbidity in patients with severe AP
[64,65]. These studies were then followed by a
multicentre German study, reporting that only bili-
ary pancreatitis patients with signs of non-resolving
biliary stasis or cholangitis/sepsis had any benefit
from ERC and sphincterotomy [66].
Indications for surgery
From a previously quite aggressive surgical attitude in
necrotizing pancreatitis, the trend has gradually be-
come more ‘conservative’. At present, surgery in
pancreatic necrosis is rarely indicated during the first
2 weeks. Indications for surgery include infected
pancreatic necrosis, and sepsis and organ failure that
do not respond to conventional treatment. Further-
more, abscess formation requires drainage. It is
important to emphasize that cholecystectomy in
gallstone-induced AP should be performed during
the same hospital stay or at least in immediate
association with the acute episode, as 10% of cases
will recur within a 46 week period with a new attack
of AP [43].
Pseudocysts and complications
Complications during the acute phase include devel-
opment of sepsis and organ failure, and in the longer
term, abscess formation, development of pseudocysts
or pancreatic insufficiency, both exocrine and endo-
crine, are to be considered. Pancreatic pseudocysts
occur in about 5% of all patients with AP. A variety of
treatment modes exist and for most, a gradual
increase in ‘invasiveness’ in the treatment could be
practised. Thus, conservative management can be
performed, not only for small size cysts but also for
larger (] 8 cm pseudocyst) without an increase in the
number of recurrences [67]. In cases of treatment
failure (non-resolving pseudocysts), or when symp-
toms require drainage, percutaneous puncture and
drainage may be tried, although keeping in mind that
the recurrence rate may be high, especially if com-
munication with the main pancreatic duct exists. In
these situations, the insertion of a cystogastrostomy,
either by the percutaneous or endoscopic route,
should be considered. However, the selection of
patients is important  excluding cases with a need
for debridement of necrotic tissue or patients with
major ongoing infection. Internal surgical drainage
and necrosectomy still play a role, but note that this
can be performed in a less invasive manner, either
laparoscopically or endoscopically by a transgastric or
transduodenal approach.
Long-term follow-up
The effects on a long-term basis depend on the extent
of the pancreatic necrosis during the acute phase and,
of course, reiterated ‘trauma’ by recurrent episodes of
AP. Following the acute phase of pancreatitis, a slow
recovery has been noted in the exocrine dysfunction
[68]. At long-term follow-up, chronic pancreatitis
develops in about 20% of patients and diabetes
mellitus in up to 30%. However, results overall are
promising, with patients regaining a good pancreatic
function and quality of life, although after a quite
prolonged period of rehabilitation [69,70].
In conclusion, cornerstones in the management of
AP include restoration and maintenance of micro-
circulation so as to minimize ischaemia and reperfu-
sion injury, thus emphasizing the importance of initial
and adequate fluid resuscitation. The integrity of the
gut barrier function is also important, in which, to
some extent, early enteral oral nutrition may be of
benefit. The value of immunonutrition and probiotics
needs further studies, as does the optimal timing of
enteral nutrition. Lessons are to be learned from
critical illness in general concerning how to optimize
organ supportive therapy, the use of low dose steroids
and intensive insulin treatment/blood glucose control.
The use of prophylactic antibiotics in severe necrotiz-
ing pancreatitis is now questioned. Surgical interven-
tion against pancreatic necrosis has come to be much
more selective than before and the same is true for
indications for ERC and sphincterotomy. Recurrent
gallstone-induced pancreatitis could, however, in al-
most all cases be avoided by early cholecystectomy
and clearance of the bile ducts. In general the long-
term results are quite satisfying. Further research is
needed to achieve improved future outcome, not least
to clarify underlying pathophysiological mechanisms
and the dynamics of the disease process. Updated
guidelines should be provided and available to sup-
port the management of patients with AP.
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